Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Investments, and Licenses (Details Textual)

v2.4.0.6
Acquisitions, Investments, and Licenses (Details Textual)
1 Months Ended 6 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended 6 Months Ended 1 Months Ended 6 Months Ended 1 Months Ended 1 Months Ended 1 Months Ended
Aug. 31, 2011
Jun. 30, 2012
USD ($)
Dec. 29, 2011
USD ($)
Oct. 13, 2011
USD ($)
Jan. 28, 2011
USD ($)
Dec. 31, 2010
USD ($)
Jun. 30, 2012
TESARO [Member]
USD ($)
Jun. 30, 2012
Hsiao And Lerner [Member]
Jun. 30, 2012
Fabrus And Drs Frost [Member]
Sep. 30, 2009
Cocrystal Discovery Inc [Member]
Aug. 31, 2011
Neovasc Inc [Member]
USD ($)
Aug. 31, 2011
Neovasc Inc [Member]
CAD
Jun. 30, 2012
Neovasc Inc [Member]
USD ($)
Jun. 30, 2012
Neovasc Inc [Member]
USD ($)
Feb. 29, 2012
Chromadex Corporation [Member]
USD ($)
Jun. 30, 2012
Chromadex Corporation [Member]
USD ($)
Feb. 29, 2012
Biozone Pharmaceuticals Inc [Member]
USD ($)
Jun. 10, 2009
Sorrento [Member]
USD ($)
Apr. 30, 2012
ALS acquisition [Member]
USD ($)
Jun. 30, 2012
FineTech Acquisition [Member]
USD ($)
Dec. 31, 2011
Claros Diagnostics [Member]
USD ($)
Oct. 31, 2011
Claros Diagnostics [Member]
USD ($)
Jun. 30, 2012
Claros Diagnostics [Member]
USD ($)
Oct. 13, 2011
Claros Diagnostics [Member]
USD ($)
Nov. 30, 2010
Investments [Member]
Fabrus LLC [Member]
USD ($)
Sep. 30, 2009
Investments [Member]
Cocrystal Discovery Inc [Member]
USD ($)
Jun. 30, 2012
Investments [Member]
Sorrento Therapeutics Inc [Member]
USD ($)
Jun. 10, 2009
Investments [Member]
Sorrento Therapeutics Inc [Member]
USD ($)
Oct. 31, 2011
Investments [Member]
Teva Pharmaceutical Industries Ltd [Member]
Cocrystal Discovery Inc [Member]
USD ($)
Jun. 30, 2012
Fabrus And Drs Frost [Member]
Jun. 30, 2012
Fabrus And Drs Frost [Member]
Gamma Trust [Member]
Acquisition and Investments (Textual) [Abstract]                                                              
Cash acquired in acquisition                                       $ 2,000,000     $ 351,000                
Purchase consideration     27,700,000                               4,000,000 28,179,000     32,452,000                
Paid in cash     10,000,000   10,000,000                           2,400,000         10,000,000              
Purchase Consideration in cash at closing into a separate escrow account                                     800,000                        
Amount paid upon the legal registration                                     800,000                        
Plus liabilities paid         600,000                                                    
Paid at closing         500,000                                                    
Paid in shares of our common stock     17,700,000                                         22,500,000              
Market value per share     $ 4.90                                         $ 5.04     $ 0.27        
Closing sales price per share of common stock   $ 4.84         $ 13.99                 $ 0.69           $ 4.45                  
Stock consideration                                           5,000,000                  
Claim against the escrow certain undisclosed liabilities                                         200,000                    
Additional payment to common stock       19,125,000                                                      
Working capital surplus                                       500,000                      
Par value                     $ 1.25           $ 0.20                            
Purchase an additional shares                     1,000,000 1,000,000                                      
Promissory notes maturity date                                 Feb. 24, 2014                            
Par value                             $ 0.75   $ 0.40                            
unrealized loss in Comprehensive Loss                               100,000                              
Warrants at their estimated fair value                     700,000                                        
Options were granted at (Canadian) per share                       1.00                                      
Vest Shares annually over                     3 years 3 years                                      
Date of grant and will recognize the revenue over                     4 years 4 years                                      
Valued the options using the Black-Scholes-Merton Model                     800,000                                        
Unrealized loss on option received from investment                         100,000                                    
Closing share price received from investment                       1.20                                      
Purchase of common stock shares                     2,000,000 2,000,000     1,333,333                                
Invested in ChromaDex Corporation common shares                     2,000,000       1,000,000     2,300,000                   2,300,000      
Financing for variable interest entities                                                 2,100,000            
Equity position           700,000                                                  
Purchase of Convertible Series A Preferred Stock                   1,701,723                                          
Warrants duration 2 years                               10 years                            
Private placement                             3,700,000                                
Purchase of 10 % secured convertible promissory notes                                 1,700,000                            
Warrants to purchase Common shares                                 8,500,000                            
Ownership percentage of variable interest entity by related party group               24.00%                                             16.00%
Unrealized gain                     200,000                                        
Un realized loss on warrant                         400,000 400,000                                  
Unrealized gains on option received from investment                         200,000 18,000                                  
Unrealized gain on investment available for sale   5,684,000         5,300,000                                                
Fabrus and Drs. Frost, Hsiao voting stock                                                           13.00%  
Investment in variable interest entities                                                   2,500,000     7,500,000    
Neovasc granted common stock options                     913,750 913,750                                      
Percentage in board of managers                 40.00%                                            
Total assets of equity method investees   22,700,000                                                          
Total liabilities of equity method investees   2,000,000                                                          
Net losses of equity method investees   7,800,000                                                          
Acquisition and Investments (Additional Textual) [Abstract]                                                              
Equity position           $ 700,000